Merck After Vioxx: No Merger, But No Big Near-Term Launches
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed